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Abstract
Purpose: To prospectively examine the risk of developing Lhermitte’s sign (LS) in patients with lymphoma treated
with modern-era chemotherapy followed by consolidation intensity-modulated radiation therapy.
Methods: We prospectively interviewed all patients with lymphoma who received irradiation to the mediastinum
from July 2011 through April 2014. We extracted patient, disease, and treatment-related variables from the medical
records of those patients and dosimetric variables from treatment-planning systems and analyzed these factors to
identify potential predictors of LS with Pearson chi-square tests.
Results: During the study period 106 patients received mediastinal radiation for lymphoma, and 31 (29 %)
developed LS. No correlations were found between LS and any of the variables examined, including total
radiation dose, maximum point dose to the spinal cord, volume receiving 105 % of the dose, and volumes
receiving 5 or 15 Gy.
Conclusion: In this group of patients, treatment with chemotherapy followed by intensity-modulated radiation
therapy led to 29 % developing LS; this symptom was independent of radiation dose and seemed to be an
idiosyncratic reaction. This relatively high incidence could have resulted from prospective use of a structured interview.
Background
Radiation therapy (RT) to the mediastinum and thoracic
regions, especially to the heart and lungs, has been asso-
ciated with various forms of toxicity [1–4]. Another less
well studied symptom, Lhermitte’s sign (LS), has been
linked with RT to the spine cord. LS, known colloquially
as “barber’s chair phenomenon,” manifests as a transient
electric shock-like sensation or tingling in the neck that
radiates down the spine and into the extremities. It can
occur spontaneously or can be triggered by movements
such as neck flexion, walking, or, less commonly, by ex-
tension or rotation of the neck [5, 6]. LS was first ob-
served in patients with multiple sclerosis by Marie and
Chatelin in 1917 but was not recognized by the neurology
community until it was reported by Jean Lhermitte in
1924 [7]. Although LS is most commonly associated with
multiple sclerosis, it can also occur in other demyelinating
conditions such as neuromyelitis optica or as a side effect
of RT to the cervical or thoracic spinal cord [8–10]. The
latter condition, termed radiogenic LS, is caused by re-
versible demyelination of ascending sensory neurons at
the dorsum columns due to inhibition of oligodendrocyte
proliferation after irradiation of the cervical or thoracic
spinal cord [11–13]. Once the oligodendrocytes recover
and myelin is resynthesized, the symptoms subside. The
symptoms of LS usually begin within a few months of
completion of RT and are transient. This is in stark con-
trast to radiation myelitis, in which symptoms generally
develop 1 year or more after radiation and progress to
permanent spinal cord injury. Although LS is not usually
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delayed radiation myelopathy causing paralysis may be
preceded by LS [14].
The reported incidence of LS among patients receiving
two-dimensional (2D) RT without chemotherapy to the
cervical or thoracic spinal cord has ranged from 3.6 to
13 % [10, 14–16]. However, a recent study reported LS
in 21 % of patients receiving chemotherapy concomitant
with intensity-modulated radiation therapy (IMRT) for
head and neck tumors [17]. Reasoning that patients re-
ceiving RT for lymphoma may also be at increased risk
of LS, we prospectively examined the incidence of LS in
a series of consecutive patients treated with RT to the
mediastinum and thorax, and sought to identify potential
predictive factors for the occurrence of radiogenic LS.
Methods
After receiving institutional review board approval to con-
duct this study, we prospectively identified and followed
116 consecutive patients with a confirmed diagnosis of
lymphoma treated with chemotherapy followed by conso-
lidative RT to the mediastinum between July 2011 and
April 2014 at a single institution. Ten patients had to be
excluded since we could not get in touch with them and
they failed to come back for a follow up. All patients but
one were treated with IMRT using a “butterfly” field
arrangement to sites involved with disease [18]. We
reviewed the type and number of chemotherapy cy-
cles. All patients were given structured interviews at
the completion of RT and at every follow-up visit,
either in person in the clinic or by phone for those
who did not return for follow-up. The timing for fol-
low up was every 3 months for 2 years for those who
did not develop the sign, and until resolution of
symptoms for those who did. Specific questions were
asked about the development of LS as follows: “have
you experienced any shooting-like pain, feeling of
electric-like shocks or sharp pain in your neck or
back that radiates to your arms or legs,” patients who
answered yes were further asked about the date of oc-
currence, intensity, and duration of symptoms. Other
questions were asked about the presence of neuropathy,
tingling, in their hands and feet as well as symptoms of
bleomycin toxicity (in patients who received bleomycin),
such as shortness of breath, coughing, and or low-grade
fever. These are the symptoms linked to the use of
Bleomycin, an antibiotic agent with antitumor activity,
including bronchiolitis obliterans with organizing pneu-
monia, esosinophilic hypersensitivity. Patient charac-
teristics extracted from the medical records included
age, sex, histopathologic diagnosis, site of disease,
type of chemotherapy, and RT modality used. Other
dosimetric information retrieved from RT treatment-
planning systems included total radiation dose, dose
per fraction, and spinal cord volumes treated to the
Table 1 Patient characteristics
Characteristic Value or no. of patients (%)
No LS (n = 75) With LSa (n = 31)
Age, years
Median (range) 37 (19–73) 32.0 (18–61)
Sex
Female 40 (53) 21 (68)
Male 35 (47) 10 (32)
Ethnicity
Caucasian 59 (78.6) 25 (81)
African-American 4 (5.4) 2 (6)
Hispanic 10 (13.4) 4 (12)
Mid-eastern 2 (2.6) 0
Histology
Hodgkin lymphoma 56 (75) 26 (84)
Non-Hodgkin lymphoma 19 (25) 5 (16)
Disease stage
I 3 (4) 3 (10)
II 55 (73.5) 24 (77)
III 2 (3) 2 (6.5)





IMRT 71 (95) 29 (94)
IMRT & 3D AP/PA 3 (4) 1 (3)
Protons 1 (1) 1 (3)
RT dose, Gy
Mean (range) 32.9 (20–46) 33.2 (30.6–46.6)
≤30.6 49 (65) 22 (71)
>30.6 26 (35) 9 (29)
30–36 10 (13) 2 (6.5)
36–45 16 (22) 7 (22.5)
Peripheral neuropathyb
Yes 35 (47) 16 (52)
No 39 (52) 14 (45)
Unknown 1 (1) 1 (3)
Bleomycin toxicityb
Yes 62 (83) 7 (23)
No 3 (4) 24 (77)
Decreased lung functionc
Yes 10 (13) 11 (35)
No 65 (87) 20 (65)
Abbreviations: IMRT, intensity-modulated radiation therapy; 3D AP/PA, three-
dimensional conformal radiation therapy with
anteroposterior/posteroanterior fields
aLS at some time during follow-up
bAfter chemotherapy but before radiation therapy
cOut of the 106 patients pulmonary function tests were performed in only
43 patients
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full prescription dose (V100%) and 105 % of the prescribed
dose (V105%), to 5 Gy and 15 Gy (V5 and V15), and the
maximum point dose (Dmax). Neuropathy and bleomycin
pneumonitis, both considered dose independent were
evaluated, this was done in an effort to record other
toxicities related to therapy. For instance, neuropathy
potentially related to vinblastine, hypothesizing that
side effects such as these are similar to LS in their
unpredictability and lack of dose dependence. Clinical
and dosimetric factors were compared by using Fisher
exact test for patients who did or did not develop LS.
Results
Patient characteristics
Patient characteristics are shown in Table 1. During
the study period, a total of 106 patients met the stated
inclusion criteria and were prospectively followed. The
median age at diagnosis of primary disease was 34 years
(range 18–61 years). Most patients (57 %) were female;
and 82 had Hodgkin lymphoma and 24 non-Hodgkin
lymphoma. Of the 24 non-Hodgkin lymphomas, 11 were
diffuse large B cell, 4 were T-cell lymphoblastic, 5 primary
mediastinal, 1 gray zone, 1 marginal zone, and 2 mixed
follicular and large B-cell lymphomas. Sixty-eight patients
received ABVD chemotherapy (doxorubicin, bleomycin,
vinblastine, and dacarbazine), of whom 27 patients did
not receive bleomycin. Other chemotherapy regimens
included rituximab, cyclophosphamide, doxorubicin, vin-
cristine, prednisone [R-CHOP]; hyperfractionated cyclo-
phosphamide, vincristine, doxorubicin and dexamethasone
[R-HCVAD], or R-EPOCH by adding etoposide. The risk
of LS did not seem to be associated with type of chemo-
therapy or number of cycles (p = 0.43), Table 2 details the
chemotherapy regimens and number of cycles used.
All patients but one received radiation to involved
sites only, the current accepted standard of care, and all
but two received IMRT (Fig. 1), [19, 20]. Additional
techniques such as use of an inclined board [21], inspir-
ation breath-hold, and butterfly IMRT planning [18]
were used to spare dose-limiting structures within the
radiation field including heart, lung, and breasts.
Incidence and risk factors for Lhermitte’s sign
Thirty-one patients (29 %) developed LS. Of those pa-
tients, 22 received 30.6 Gy in 17 fractions, one re-
ceived 36 Gy in 20 fractions, and one 39.6 Gy in 22
fractions; the other 7 patients were treated with a se-
quential boost technique, with total doses ranging from
Fig. 1 Representative axial (top), coronal (left), and sagittal (right) views of treatment plans for a patient receiving intensity-modulated radiation
therapy for mediastinal lymphoma
Table 2 Details of the chemotherapy regimens and number of
cycles between patients with and without LS
Chemotherapy No LS LS
2–4 ABVD/AVD 24 9
>4 ABVD/AVD 22 11
≥6 R-CHOP 2 1
≥6 R-EPOCH 6 2
≥6 HyperCVAD 1 0
Salvage 20 7
ABVD/AVD: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
R-EPOCH: Rituximab, Etoposide, Prednisolone, Vincristin,
Cyclophosphamide, Doxorubicin
HyperCVAD: Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone,
Methotrexate, Cytarabine
Salvage: Multiple lines of chemotherapy +/− Stem cell transplantation
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36 Gy to 46.6 Gy. The mean prescribed dose was 33.2 Gy
(range 30.6 − 46.6 Gy), and the spinal cord Dmax was
33.5 Gy (range 28.0–43.5 Gy). Nine patients had measur-
able “hot spots” (defined as ≥105 % of the prescribed dose)
in the spinal cord, with a mean volume of 2.7 cm3
(range 0.02–14.6 cm3) (Table 3).
The mean time to development of symptoms was
3 months (range 2 weeks to 5 months) after comple-
tion of RT; however, one patient developed LS after
completing chemotherapy and before starting RT. The
average time to noticeable improvement was 8 months
(range 2–16 months), but 5 patients had ongoing
symptoms for up to 1 year after finishing RT. One
patient with severe symptoms evoked by walking for
short distances was assessed by magnetic resonance
imaging (MRI) of the spine twice, at the onset of symptoms
and 6 months later; both MR images showed prominent
dilated veins but no sign of demyelination (Fig. 2).
At the completion of chemotherapy but before RT was
begun, 16 of 31 patients with LS (52 %) and 35 of those
without LS (47 %) had peripheral neuropathy; 11 of 31
patients (35 %) with LS had pulmonary function
decreased relative to baseline at that time, which in 7 pa-
tients was thought to reflect bleomycin-induced lung
toxicity (bleomycin was subsequently discontinued).
Because pulmonary function tests were completed by
only 43 of the 106 patients at both time points (and for
those who received ABVD, at the discretion of the treating
physician), we could not compare pulmonary function
between groups that did or did not develop LS.
Finally, we evaluated several dosimetric variables, in-
cluding the spinal cord volume (cm3) that received 5 Gy,
15 Gy, or 105 % of the prescribed dose as well as the
maximum point dose, for their potential association with
the development of LS (Table 4). None of these variables
showed any statistically significant relationship with LS.
Discussion
In this prospective evaluation of LS after modern-day
RT for patients with lymphoma, we found an incidence
of 29 % with a median time to development of 3 months,
but we could not identify any baseline or dosimetric
characteristics associated with its development. At 29 %
this rate was higher than those of previous studies in-
volving use of 2D RT (3.6–13 %) or chemoradiation with
IMRT for head and neck cancer (21 %) [17], despite our
use of relatively low radiation doses.
The lack of correlation between radiation dose or frac-
tion size and LS in our study is in contrast to previous
studies in which LS was linked with higher dose per
fraction (≥2 Gy/fraction), spinal cord doses >45 Gy, and
altered fractionation [15]. One group, for example, found
that a V45 of the cervical spinal cord of ≥14.15 cm
3 was
associated with LS in patients with laryngeal or oropha-
ryngeal cancer [22]. Another group showed that frac-
tions larger than 2 Gy were also associated with LS [16].
The lack of correlation in our study, in which 1.8-Gy
daily fractions were used with a spinal cord Dmax of
43.5 Gy, suggests that additional factors contribute to
the development of LS, or that LS is idiosyncratic. Also,
11 of 31 of patients who developed LS also developed
decreased lung function attributed to bleomycin, which
has been established by others as an allergic pulmonary
reaction [23–25]. It is worth to add here that we chose
to evaluate cord volumes instead of percentages because
the entirety of the cord is not usually included in the
Table 3 Spinal cord doses in 31 patients who developed
Lhermitte’s sign
Total dose, Spinal cord Location of
Patient ID Gy Dmax Gy (%) Dmax Cord V105%, cm
3
1 30.6 33.04 (108) T4–T5 3
2 30.6 28.51 (93) — 0
3 30.6 33.98 (111) T3 2.26
4 30.6 29.1 (95) — 0
5 30.6 31.84 (104) T5–T6 0
6 30.6 35.81 (117) T3–T8 14.6
7 30.6 31.02 (101) — 0
8 30.6 30.10 (98) — 0
9 30.6 29.93 (98) — 0
10 30.6 34.66 (113) T5 0.5
11 30.6 30.85 (101) — 0
12 30.6 31.96 (104) — 0
13 30.6 28.06 (92) — 0
14 30.6 30.94 (101) — 0
15 30.6 34.67 (113) T4–T7 1.1
16 30.6 30.01 (98) — 0
17 30.6 32.18 (105) T9 0
18 29.75 31.19 (105) — 0
19 30.6 31.72 (104) — 0
20 30.6 33.12 (108) T4 0.8
21 30.6 33.06 (108) T4 1.3
22 30.6 37.23 (105) — 0
23 30.6 38.78 (108) T6 0.02
24 30.6 36.21 (101) — 0
25 37.4 39.34 (105) — 0
26 39.6 34.13 (109) T1-T2; T5; T8 0.8
27 41.4 38.69 (93) — 0
28 42.0 31.02 (74) — 0
29 46.6 39.40 (85) — 0
30 41.4 43.51 (105) — 0
31 36.0 35.48 (99) — 0
D max = maximum point dose
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treatment plans, and thus the volume of the cord receiv-
ing a certain dose may be more accurate than the per-
centage of the cord, which is generally provided in the
dose-volume histogram.
Our study also differs from others in that previous re-
ports of LS focused on patients with cancer of the head
and neck, whereas our study was limited to patients who
received radiation to the thorax and thoracic spine [17].
Also, concurrent chemoradiation has been linked with
higher LS incidence, perhaps due to disruption of the
blood–brain barrier by radiation and subsequent pene-
tration of cytotoxic agents to the central nervous system
[26]. In our study, all patients received systemic chemo-
therapy, but the chemotherapy was delivered before the
RT, so the aforementioned rationale does not seem
apply in this case. Third, some case reports suggest
that chemotherapy alone, especially cisplatin and doce-
taxel, given alone or after stem cell transplantation, can
cause LS [27–30]. However, use of ABVD has not been as-
sociated with LS, and thus the contribution of this type of
chemotherapy, if any, to the development of LS in patients
with lymphoma remains unclear. Increasing age has been
linked inversely with LS, with one study showing younger
age to be a risk factor for developing LS [22] and another
showing a LS to be less common among patients >60 years
old [10]. The young age of the patients in the current
study (median 32 years in the group with LS and 37 years
in those without LS) may explain the relatively high inci-
dence of LS in this study.
One caveat in interpreting our results is bias intro-
duced by our prospective use of interviews at each
follow-up visit, which may have increased patients’
awareness of subclinical LS or related symptoms. In-
deed, several patients made comments such as “so
that’s what that was.” Another shortcoming of our
study was our inability to validate previously identified
risk factors for LS development, leading us to speculate
Fig. 2 T1-weighted sagittal (left) and axial (right) magnetic resonance images with contrast show dilated subdural veins in a patient with Lhermitte
sign and severe symptoms upon walking
Table 4 Comparison of dosimetric variables and treatment-related
toxicities between patients with and without LS
P Test
All Patients No LS Value
Characteristic (n = 106) LS (n = 75) (n = 31)
Volume receiving
5 Gy, cm3
Median 29.9 29 31 0.25 Median
Mean 32.8 33.2 31.7
Range 9.7–233 9.7–233 15.3–56.5
Volume receiving
15 Gy, cm3
Median 23 22.6 25.9 0.25 Median
Mean 24.8 24.5 25.4
Range 8.8–51.7 8.8–51.7 13.2–43
Spinal cord maximum
dose, Gy
Median 32.2 32.2 33 0.97 Median
Mean 32.7 32.4 33.5
Range 18.2–47.2 18.2–47.2 28–43.5
Spinal cord maximum
dose, %
Median 100 100 100 0.33 Median
Mean 99 98 100
Range 64–118 64–118 74–117
Bleomycin toxicity
No 62 45 17 0.40 Fisher’s
exact
Yes 17 10 7 0.37
No bleomycin 27 20 7
Peripheral neuropathy
No 53 39 14 0.43 Fisher’s
exact
Yes 53 36 17 0.51
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that LS is not dose-dependent, as is true for neuropathy
secondary to vincristine or vinblastine, or declines in
lung function attributable to bleomycin. Nevertheless,
this is one of the few studies to examine the incidence of
LS after chemotherapy and radiation for lymphoma, and it
is the only study to our knowledge to be conducted
prospectively.
Conclusions
This report represents the first prospective evaluation of
LS after consolidation RT for patients with lymphoma.
We observed a 29 % incidence of LS with a median time
to development of 3 months. However, we could not
identify any baseline or dosimetric characteristics associ-
ated with its development, leading us to conclude the
development of LS in this clinical scenario may be an
idiosyncratic reaction independent of radiation dose or
fraction size. Our findings add to the body of the litera-
ture on the occurrence of LS, and confirmation of our
findings by others would be helpful for determining the
significance of LS among patients receiving thoracic
radiation.
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